PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24215511-0	2013	Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.	Docetaxel	94-103	ribonucleotide reductase catalytic subunit M1	Homo sapiens	20-24	
24215511-1	2013	BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients.	Docetaxel	269-278	ribonucleotide reductase catalytic subunit M1	Homo sapiens	131-166	
24215511-1	2013	BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients.	Docetaxel	269-278	ribonucleotide reductase catalytic subunit M1	Homo sapiens	168-172	
24215511-1	2013	BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients.	Docetaxel	304-313	ribonucleotide reductase catalytic subunit M1	Homo sapiens	131-166	
24215511-1	2013	BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients.	Docetaxel	304-313	ribonucleotide reductase catalytic subunit M1	Homo sapiens	168-172	
23359225-1	2012	OBJECTIVE: Experimental evidence suggests that the overexpression of breast cancer-specific tumor suppressor protein 1 (BRCA1) gene enhances sensitivity to docetaxel and resistance to cisplatin and ribonucleotide reductase M1 (RRM1) gene overexpression enhances resistance to gemcitabine.	Docetaxel	156-165	ribonucleotide reductase catalytic subunit M1	Homo sapiens	227-231	
24647522-6	2014	In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007).	Docetaxel	40-49	ribonucleotide reductase catalytic subunit M1	Homo sapiens	3-7	
18414411-2	2008	The mRNA expression of RRM1 and RRM2 in tumours from lung adenocarcinoma patients treated with docetaxel/gemcitabine was assessed and the results correlated with clinical outcome.	Docetaxel	95-104	ribonucleotide reductase catalytic subunit M1	Homo sapiens	23-27	
15277258-4	2004	We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel-cisplatin-treated stage IV NSCLC patients.	Docetaxel	138-147	ribonucleotide reductase catalytic subunit M1	Homo sapiens	74-78